Neoglycan anticancer agents and uses thereof

The instant invention describes the production of neoglycans, compounds capable of inhibiting tumor cell growth. The heparan sulfate proteoglycan syndecan-1 is a tumor suppressor molecule that inhibits growth and induces apoptosis in several cancer cell lines. Attempts to create synthetic analogues...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PUMPHREY CARLA Y, SANDERSON RALPH D
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	PUMPHREY CARLA Y SANDERSON RALPH D
description	The instant invention describes the production of neoglycans, compounds capable of inhibiting tumor cell growth. The heparan sulfate proteoglycan syndecan-1 is a tumor suppressor molecule that inhibits growth and induces apoptosis in several cancer cell lines. Attempts to create synthetic analogues of syndecan-1 by carbodiimide (EDAC) conjugation of a protein scaffold and GAG surprisingly revealed that the protein component is not required. Neoglycans consisting of EDAC-modified heparin and EDAC-modified chondroitin sulfate (CS), respectively named neoheparin and neo-chondroitin sulfate (neoCS), were found to inhibit multiple myeloma cell viability. Further analysis revealed the neoglycan compounds severely reduced cell viability of multiple myeloma, breast cancer and normal laboratory cell lines and peripheral blood mononuclear cells through the induction of apoptosis. Neoglycans provide a new class of GAG chain-based anticancer therapeutics.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2002013264A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2002013264A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2002013264A13</originalsourceid><addsrcrecordid>eNrjZNDxS81Pz6lMTsxTSMwryQTSyalFConpqXklxUCRFIXS4tRihZKM1KLU_DQeBta0xJziVF4ozc2g7OYa4uyhm1qQH59aXJCYnJqXWhIfGmxkYGBkYGhsZGbiaGhMnCoAPl0qqQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Neoglycan anticancer agents and uses thereof</title><source>esp@cenet</source><creator>PUMPHREY CARLA Y ; SANDERSON RALPH D</creator><creatorcontrib>PUMPHREY CARLA Y ; SANDERSON RALPH D</creatorcontrib><description>The instant invention describes the production of neoglycans, compounds capable of inhibiting tumor cell growth. The heparan sulfate proteoglycan syndecan-1 is a tumor suppressor molecule that inhibits growth and induces apoptosis in several cancer cell lines. Attempts to create synthetic analogues of syndecan-1 by carbodiimide (EDAC) conjugation of a protein scaffold and GAG surprisingly revealed that the protein component is not required. Neoglycans consisting of EDAC-modified heparin and EDAC-modified chondroitin sulfate (CS), respectively named neoheparin and neo-chondroitin sulfate (neoCS), were found to inhibit multiple myeloma cell viability. Further analysis revealed the neoglycan compounds severely reduced cell viability of multiple myeloma, breast cancer and normal laboratory cell lines and peripheral blood mononuclear cells through the induction of apoptosis. Neoglycans provide a new class of GAG chain-based anticancer therapeutics.</description><edition>7</edition><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2002</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20020131&DB=EPODOC&CC=US&NR=2002013264A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20020131&DB=EPODOC&CC=US&NR=2002013264A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PUMPHREY CARLA Y</creatorcontrib><creatorcontrib>SANDERSON RALPH D</creatorcontrib><title>Neoglycan anticancer agents and uses thereof</title><description>The instant invention describes the production of neoglycans, compounds capable of inhibiting tumor cell growth. The heparan sulfate proteoglycan syndecan-1 is a tumor suppressor molecule that inhibits growth and induces apoptosis in several cancer cell lines. Attempts to create synthetic analogues of syndecan-1 by carbodiimide (EDAC) conjugation of a protein scaffold and GAG surprisingly revealed that the protein component is not required. Neoglycans consisting of EDAC-modified heparin and EDAC-modified chondroitin sulfate (CS), respectively named neoheparin and neo-chondroitin sulfate (neoCS), were found to inhibit multiple myeloma cell viability. Further analysis revealed the neoglycan compounds severely reduced cell viability of multiple myeloma, breast cancer and normal laboratory cell lines and peripheral blood mononuclear cells through the induction of apoptosis. Neoglycans provide a new class of GAG chain-based anticancer therapeutics.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2002</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDxS81Pz6lMTsxTSMwryQTSyalFConpqXklxUCRFIXS4tRihZKM1KLU_DQeBta0xJziVF4ozc2g7OYa4uyhm1qQH59aXJCYnJqXWhIfGmxkYGBkYGhsZGbiaGhMnCoAPl0qqQ</recordid><startdate>20020131</startdate><enddate>20020131</enddate><creator>PUMPHREY CARLA Y</creator><creator>SANDERSON RALPH D</creator><scope>EVB</scope></search><sort><creationdate>20020131</creationdate><title>Neoglycan anticancer agents and uses thereof</title><author>PUMPHREY CARLA Y ; SANDERSON RALPH D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2002013264A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2002</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>PUMPHREY CARLA Y</creatorcontrib><creatorcontrib>SANDERSON RALPH D</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PUMPHREY CARLA Y</au><au>SANDERSON RALPH D</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Neoglycan anticancer agents and uses thereof</title><date>2002-01-31</date><risdate>2002</risdate><abstract>The instant invention describes the production of neoglycans, compounds capable of inhibiting tumor cell growth. The heparan sulfate proteoglycan syndecan-1 is a tumor suppressor molecule that inhibits growth and induces apoptosis in several cancer cell lines. Attempts to create synthetic analogues of syndecan-1 by carbodiimide (EDAC) conjugation of a protein scaffold and GAG surprisingly revealed that the protein component is not required. Neoglycans consisting of EDAC-modified heparin and EDAC-modified chondroitin sulfate (CS), respectively named neoheparin and neo-chondroitin sulfate (neoCS), were found to inhibit multiple myeloma cell viability. Further analysis revealed the neoglycan compounds severely reduced cell viability of multiple myeloma, breast cancer and normal laboratory cell lines and peripheral blood mononuclear cells through the induction of apoptosis. Neoglycans provide a new class of GAG chain-based anticancer therapeutics.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US2002013264A1
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title	Neoglycan anticancer agents and uses thereof
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A55%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PUMPHREY%20CARLA%20Y&rft.date=2002-01-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2002013264A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true